TRIAL DETAIL

A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors

Drug:
Trial Name:
A Study of CS1001 in Subjects With Advanced or Refractory Solid Tumors
NCT#:
Conditions:
Solid Tumors
Status:
Recruiting
Phase:
1/2
Start Date 12/13/2019
Age of Trial (yrs) .7
Treatment Phase:
Gleevec-resistant
Drug Category:
PD-L1 inhibitor + TKI
Strategy:
Immune checkpoint inhibitor enhanced by TKI
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
CS1001/Regorafenib-101
Sponsor:
CStone Pharmaceuticals
Patient Contact:
Wendie Yuan +86 21 61097678 cstonera@cstonepharma.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral Intravenous
Trial Notes:

Trial Links

Trial Results

Drug Information

CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
 

Trial Sites

Name
Address
City
State
Zip
Country
520 South Road
Kurrulta Park
South Australia
5037
Australia